Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16381629rdf:typepubmed:Citationlld:pubmed
pubmed-article:16381629lifeskim:mentionsumls-concept:C0006142lld:lifeskim
pubmed-article:16381629lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:16381629lifeskim:mentionsumls-concept:C0002871lld:lifeskim
pubmed-article:16381629lifeskim:mentionsumls-concept:C0332174lld:lifeskim
pubmed-article:16381629lifeskim:mentionsumls-concept:C0357126lld:lifeskim
pubmed-article:16381629lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:16381629lifeskim:mentionsumls-concept:C0937950lld:lifeskim
pubmed-article:16381629lifeskim:mentionsumls-concept:C0282440lld:lifeskim
pubmed-article:16381629lifeskim:mentionsumls-concept:C1096777lld:lifeskim
pubmed-article:16381629lifeskim:mentionsumls-concept:C1442457lld:lifeskim
pubmed-article:16381629pubmed:issue5lld:pubmed
pubmed-article:16381629pubmed:dateCreated2005-12-29lld:pubmed
pubmed-article:16381629pubmed:abstractTextCurrent chemotherapy regimens for breast cancer result in high incidences of anemia, which can be treated with erythropoietic agents. The relative efficacy of darbepoetin alfa and epoetin alfa was explored in this phase II, open-label, randomized, multicenter trial in anemic patients with breast cancer receiving chemotherapy.lld:pubmed
pubmed-article:16381629pubmed:languageenglld:pubmed
pubmed-article:16381629pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16381629pubmed:citationSubsetIMlld:pubmed
pubmed-article:16381629pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16381629pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16381629pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16381629pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16381629pubmed:statusMEDLINElld:pubmed
pubmed-article:16381629pubmed:monthDeclld:pubmed
pubmed-article:16381629pubmed:issn1526-8209lld:pubmed
pubmed-article:16381629pubmed:authorpubmed-author:TomitaDianneDlld:pubmed
pubmed-article:16381629pubmed:authorpubmed-author:CharuVeenaVlld:pubmed
pubmed-article:16381629pubmed:authorpubmed-author:SchwartzbergL...lld:pubmed
pubmed-article:16381629pubmed:authorpubmed-author:RossiGregGlld:pubmed
pubmed-article:16381629pubmed:authorpubmed-author:SenecalFrank...lld:pubmed
pubmed-article:16381629pubmed:authorpubmed-author:GabrailNashat...lld:pubmed
pubmed-article:16381629pubmed:authorpubmed-author:YeeLorrinLlld:pubmed
pubmed-article:16381629pubmed:issnTypePrintlld:pubmed
pubmed-article:16381629pubmed:volume6lld:pubmed
pubmed-article:16381629pubmed:ownerNLMlld:pubmed
pubmed-article:16381629pubmed:authorsCompleteYlld:pubmed
pubmed-article:16381629pubmed:pagination446-54lld:pubmed
pubmed-article:16381629pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:16381629pubmed:meshHeadingpubmed-meshheading:16381629...lld:pubmed
pubmed-article:16381629pubmed:meshHeadingpubmed-meshheading:16381629...lld:pubmed
pubmed-article:16381629pubmed:meshHeadingpubmed-meshheading:16381629...lld:pubmed
pubmed-article:16381629pubmed:meshHeadingpubmed-meshheading:16381629...lld:pubmed
pubmed-article:16381629pubmed:meshHeadingpubmed-meshheading:16381629...lld:pubmed
pubmed-article:16381629pubmed:meshHeadingpubmed-meshheading:16381629...lld:pubmed
pubmed-article:16381629pubmed:meshHeadingpubmed-meshheading:16381629...lld:pubmed
pubmed-article:16381629pubmed:meshHeadingpubmed-meshheading:16381629...lld:pubmed
pubmed-article:16381629pubmed:meshHeadingpubmed-meshheading:16381629...lld:pubmed
pubmed-article:16381629pubmed:meshHeadingpubmed-meshheading:16381629...lld:pubmed
pubmed-article:16381629pubmed:meshHeadingpubmed-meshheading:16381629...lld:pubmed
pubmed-article:16381629pubmed:meshHeadingpubmed-meshheading:16381629...lld:pubmed
pubmed-article:16381629pubmed:meshHeadingpubmed-meshheading:16381629...lld:pubmed
pubmed-article:16381629pubmed:meshHeadingpubmed-meshheading:16381629...lld:pubmed
pubmed-article:16381629pubmed:year2005lld:pubmed
pubmed-article:16381629pubmed:articleTitleTreatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.lld:pubmed
pubmed-article:16381629pubmed:affiliationNorthwest Medical Specialties, Tacoma, WA 98405, USA. mnelson@nwmedicalspecialties.comlld:pubmed
pubmed-article:16381629pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16381629pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:16381629pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16381629lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16381629lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16381629lld:pubmed